Grifols (GRFS) Current Assets (2009 - 2025)
Grifols' (GRFS) quarterly Current Assets came in at $5.9 billion in Q4 2025, down 3.51% YoY from $6.1 billion in Q4 2024, and down 3.51% on a QoQ basis from $6.1 billion in Q4 2024.
Grifols (GRFS) Current Assets (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Current Assets data on file, last reported at $5.9 billion in Q4 2025.
- Quarterly Current Assets fell 3.51% year-over-year to $5.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 billion (down 3.51% YoY) and the FY2025 annual result came in at $5.9 billion, up 21775.4% from the prior year.
- Current Assets retreated to $5.9 billion in Q4 2025, from $6.1 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $6.6 billion in Q4 2023 to a low of $4.8 billion in Q4 2022.
- A 5-year average of $5.9 billion and a median of $6.1 billion in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets jumped 67.05% — and 2022, when it slipped 24.08%.
- Tracing GRFS's Current Assets over 5 years: stood at $6.3 billion in 2021, then fell by 24.08% to $4.8 billion in 2022, then soared by 37.84% to $6.6 billion in 2023, then decreased by 7.21% to $6.1 billion in 2024, then dropped by 3.51% to $5.9 billion in 2025.
- The last three Current Assets figures came in at $5.9 billion (Q4 2025), $6.1 billion (Q4 2024), and $6.6 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.36 Bn | 632.60 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 470.47 Bn | 463.90 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 379.81 Bn | 372.67 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 303.09 Bn | 295.40 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 258.57 Bn | 253.67 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 237.19 Bn | 223.20 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 182.88 Bn | 179.70 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 161.00 Bn | 149.30 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.89 Bn | 101.73 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Grifols | 5.47 Bn | 4.47 Bn | - | 5.91 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.91 Bn |
| Dec 31, 2024 | 6.12 Bn |
| Dec 31, 2023 | 6.60 Bn |
| Dec 31, 2022 | 4.79 Bn |
| Dec 31, 2021 | 6.30 Bn |
| Dec 31, 2020 | 3.77 Bn |
| Sep 30, 2020 | 4.26 Bn |
| Mar 31, 2020 | 4.04 Bn |
| Dec 31, 2019 | 5.94 Bn |
| Sep 30, 2019 | 4.07 Bn |
| Mar 31, 2019 | 3.97 Bn |
| Dec 31, 2018 | 3.98 Bn |
| Sep 30, 2018 | 3.52 Bn |
| Jun 30, 2018 | 3.52 Bn |
| Mar 31, 2018 | 3.64 Bn |
| Dec 31, 2017 | 3.47 Bn |
| Jun 30, 2017 | 3.13 Bn |
| Dec 31, 2016 | 3.37 Bn |
| Sep 30, 2016 | 3.30 Bn |
| Jun 30, 2016 | 3.30 Bn |